251 completed, 33 terminated, 15 recruiting, 8 withdrawn. 152 Phase 3, 80 Phase 1, 68 Phase 2, 21 Phase 4, 3 Not applicable.
Follow Otsuka Pharmaceutical Development & Commercialization, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults 14C-SEP-380135 - Schizophrenia | Phase 1 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | 2026-11-01 | 2026-10-16 |
| Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab, Standard of care - IgA Nephropathy | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | 2026-10-30 | 2026-10-15 |
| A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder SEP-363856 - Generalized Anxiety Disorder | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 1120 | 2026-10-08 | 2026-10-20 |
| A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body HBM7020 - Rheumatoid Arthritis, Systemic Lupus Erythematosus | Phase 1 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 63 | 2026-09-24 | 2026-10-13 |
| A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation Centanafadine XR - Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 80 | 2026-09-01 | 2026-09-14 |
| A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder SEP-363856, Placebo - Generalized Anxiety Disorder | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 384 | 2026-08-06 | 2026-10-20 |
| A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder SEP-363856, Placebo - Generalized Anxiety Disorder | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 576 | 2026-07-28 | 2026-10-26 |
| A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney Function Repinatrabit - Phenylketonuria | Phase 1 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 32 | 2026-07-17 | 2026-08-12 |
| A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body NDI-5001 - Diabetes Insipidus | Phase 1 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | 2026-07-07 | 2026-10-20 |
| A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together Repinatrabit, EE/NE, Metformin - Healthy Volunteers | Phase 1 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 48 | 2026-03-31 | 2026-08-12 |
| Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy IRL757, Placebo - PARKINSON DISEASE (Disorder), Apathy | Phase 1 / Phase 2 | Recruiting | Integrative Research Laboratories AB | 75 | 2026-02-18 | 2026-09-03 |
| A Trial to Assess How Centanafadine Interacts With Stimulants in the Body Centanafadine, Methylphenidate, Lisdexamfetamine - ADHD | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 40 | 2026-02-05 | 2026-05-05 |
| A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults MSP-2020 - Healthy Volunteers | Phase 1 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | 2026-01-15 | 2026-08-18 |
| A Study of JNT-517 in Participants With Phenylketonuria (PKU) JNT-517, JNT-517 Matching Placebo - Phenylketonuria | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 120 | 2025-10-20 | 2026-10-21 |
| A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis Bedaquiline, Quabodepistat, Pretomanid - Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 532 | 2025-10-16 | 2026-10-26 |
| A Long-Term Study of JNT-517 in Participants With Phenylketonuria JNT-517 - Phenylketonuria (PKU) | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 240 | 2025-08-11 | 2026-05-01 |
| A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria JNT-517 Tablet, Placebo - Phenylketonuria (PKU) | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 14 | 2025-07-16 | 2026-05-13 |
| A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure OPC-131461, Placebo - Heart Failure | Phase 2 | Withdrawn | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-04-30 | 2026-04-17 | |
| A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's Sibeprenlimab, Placebo - Sjogren Disease | Phase 2 | Active not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 83 | 2025-04-23 | 2026-03-18 |
Showing 20 of 322. Sign in to see all of them.
Schizophrenia (88) · Depressive Disorder, Major (37) · Mental Disorders (25) · Attention Deficit Disorder with Hyperactivity (21) · Bipolar Disorder (16) · Psychotic Disorders (15) · Alzheimer Disease (13) · Depression (13) · Polycystic Kidney, Autosomal Dominant (10) · Psychomotor Agitation (10) · Hyponatremia (9) · Tuberculosis, Multidrug-Resistant (9) · Tuberculosis (8) · Depressive Disorder (7) · Mania (7)
Aripiprazole (86) · brexpiprazole (35) · SEP-363856 (26) · Tolvaptan (26) · OPC-67683 (12) · 1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane (11) · Escitalopram (7) · Quetiapine Fumarate (6) · Risperidone (6) · Busulfan (5) · Olanzapine (5) · Sertraline (5) · Moxifloxacin (4) · bedaquiline (4) · dextromethorphan - quinidine combination (4)
United States (251) · Poland (46) · Canada (44) · Germany (42) · Romania (39) · Hungary (36) · Bulgaria (35) · Spain (35) · United Kingdom (35) · Russia (34) · Australia (29) · France (29) · Italy (26) · Ukraine (25) · Croatia (24)
Eva Kohegyi, MD (9) · Junichi Hashimoto, PhD (6) · Aleksandar Skuban, M.D. (4) · Frank Czerwiec, MD, PhD (3) · Timothy Peters-Strickland, MD (3) · Ann Dandurand, MD (2) · Eva Kohegyi, MD, MS (2) · Frank Czerwiec, M.D., Ph.D. (2) · Kimberly Largay, MD (2) · Matthew Leoni, M.D. (2) · Stacy Wu, MD (2) · Vicente Torres, MD, PhD (2)
PMID 30508090, PMID 37250503, PMID 38085556, PMID 39356039, PMID 27188270, PMID 31577867, PMID 18832427, PMID 34901863, PMID 35235720, PMID 36191725, PMID 37349694, PMID 37656180, PMID 40681915, PMID 41533472, PMID 41961243, PMID 21731833, PMID 23106023, PMID 23585997, PMID 23585999, PMID 24766999, PMID 29985680, PMID 31014270, PMID 34894307, PMID 37099968, PMID 38421922, PMID 39108660, PMID 40607746, PMID 40852147, PMID 41055581, PMID 41591746, PMID 42474330, PMID 17105757, PMID 20816039, PMID 21731831, PMID 22027579, PMID 24138011, PMID 25151571, PMID 25711509, PMID 27208498, PMID 28204607, PMID 31708380, PMID 35404075, PMID 37986188, PMID 39558901, PMID 39749727, PMID 40847656, PMID 40859756, PMID 41439450, PMID 41689409, PMID 41849920
2019 (9), 2009 (4), 2017 (4), 2016 (3), 2018 (3), 2023 (3), 2008 (1), 2025 (1)